Condition category
Infections and Infestations
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting
Publication status

Plain English Summary

Not provided at time of registration

Trial website

Contact information



Primary contact

Mr Clinical Department -


Contact details

Hepatology Clinic
Academic Medical Center (AMC)
Department of Gastroenterology and Hepatology
Room C2-331
PO Box 22660
1100 DD

Additional identifiers

EudraCT number number

Protocol/serial number

MEC 05/148

Study information

Scientific title

Response and markers of response in chronic hepatitis B patients treated with peg-interferon alfa-2a and adefovir


Study hypothesis

There are predictive markers of treatment response (or non-response) at baseline or during early beginning of treatment.

Ethics approval

Ethics approval received from the local medical ethics committee

Study design

Non-randomised controlled trial

Primary study design


Secondary study design

Non randomised study

Trial setting


Trial type


Patient information sheet

Not available in web format, please use the contact details to request a patient information sheet


Chronic Hepatitis B Virus (HBV)


During pre-screening and at the end of treatment at 48 weeks each patient will undergo a liver biopsy.

All patients will receive PEGASYS® 180 microgram, administered subcutaneously once per week for 48 weeks and stopped thereafter. The dose of Adefovir (ADF) and dipivoxil (HEPSERA®) will be 10 mg daily for 48 weeks and stopped thereafter.

During treatment the patient has to visit the outpatient clinic 22 times for check up, to draw blood and collect urine. The latter were taken for analysis.

Intervention type



Not Applicable

Drug names

Peg-interferon alfa-2a, adefovir

Primary outcome measure

To establish the rate of response (HBV-DNA levels less than 100,000 cop/mL [17,000 IU/mL]) at end of follow-up and to determine if markers at base line and early during treatment can predict response.

Secondary outcome measures

1. To establish rate of response at levels HBV-DNA less than 10,000 cop/mL (1,700 IU/mL), less than 400 cop/mL (72 IU/mL) and at limit of detection (less than 300 cop/mL [54 IU/mL]) at end of follow-up.
2. To establish predictive markers for response of primary and secondary end points.
3. To establish the rate of HBeAg seroconversion at end of follow-up in HBeAg positive patients only.

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Male and female patients over 18 years of age
2. Positive Hepatitis B surface Antigens (HBsAg) for more than six months
3. a. for Hepatitis B 'e' Antigen (HBeAg) positive patients: HBeAg positive, anti-HBe negative and Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) more than 100,000 cop/mL (more than 17,000 IU/mL) as measured by Polymerase Chain Reaction (PCR)
b. for HBeAg negative patients: HBeAg negative for more than six months, and anti-HBeAg positive, HBV DNA (more than 100,000 cop/mL [more than 17,000 IU/mL]) as measured by PCR
4. Patients with Chronic Hepatitis B (CHB) who are either naÏve to HBV treatment, or have received and have not responded/relapsed to either conventional Interferon (IFN) or Lamivudine (LAM) in the past
5. If the patient has used LAM, the patient must have been on LAM for a period of at least six months
6. Elevated serum Alanine Aminotransferase (ALAT) more than Upper Limit of Normal (ULN) but less than or equal to 10 x ULN as determined by two abnormal values taken more than 14 days apart during the six months before the first dose of study drug with at least one of the determinations obtained during the screening period
7. A liver biopsy obtained at a maximum of one year prior to study enrollment, demonstrating liver disease consistent with chronic hepatitis B and/or more than fibrosis stage 2 (Ishak classification). Patients with cirrhosis or marked fibrosis on liver biopsy must also have a liver imaging study to rule out hepatic carcinoma.

Participant type


Age group




Target number of participants


Participant exclusion criteria

1. Patients co-infected with Hepatitis C Virus (HCV), Hepatitis D Virus (HDV), Human Immunodeficiency Virus (HIV) or who have decompensated liver disease, hepato-cellular carcinoma, pre-existing severe depression or other psychiatric disease, significant cardiac disease, significant renal disease, seizure disorders or severe retinopathy will be excluded
2. Patients who have received LAM therapy for their chronic hepatitis B within six weeks before enrolment or any other antiviral therapy for their chronic hepatitis B within six months before enrolment (e.g. IFN)
3. Patients must not have received any other systemic anti-viral, anti-neoplastic or immuno-modulatory treatment (including supraphysiologic doses of steroids or radiation)
4. Positive test at screening for anti-Hepatitis A Virus Immunoglobulin M (HAV IgM), anti-HIV, anti-HCV, HCV Ribonucleic Acid (RNA) or anti-HDV
5. Patients who are expected to need systemic antiviral therapy other than that provided by the study at any time during their participation in the study are also excluded.
Exception: patients who have had a limited (less than or equal to seven day) course of acyclovir for herpetic lesions more than one month prior to the first administration of test drug are not excluded
6. Evidence of decompensated liver disease (Child B-C)
7. Serum total bilirubin more than twice the upper limit of normal at screening
8. History or other evidence of bleeding from esophageal varices or other conditions consistent with decompensated liver disease
9. History or other evidence of a medical condition associated with chronic liver disease other than HBV (e.g., hemochromatosis, autoimmune hepatitis, metabolic liver diseases including Wilson’s disease and alfa1-antitrypsin deficiency, alcoholic liver disease, toxin exposures, thalassemia)
10. Women with ongoing pregnancy or who are breast feeding
11. Neutrophil count less than 1500 cells/mm^3 or platelet count less than 90,000 cells/mm^3 at screening
12. Hemoglobin less than 7.1 mmol/L (less than 11.5 g/dL) for females and less than 7.8 mmol/L (less than 12.5 g/dL) for men at screening
13. Serum creatinine level more than 1.5 times the ULN at screening
14. History of severe psychiatric disease, especially depression. Severe psychiatric disease is defined as major depression or psychosis, a period of treatment with an antidepressant medication or major tranquiliser at therapeutic doses for depression or psychosis for at least three months, a suicidal attempt, hospitalisation for psychiatric disease, or a period of disability due to a psychiatric disease
15. History of immunologically mediated disease (e.g., inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hemolytic anemia, scleroderma, severe psoriasis, rheumatoid arthritis)
16. History or other evidence of chronic pulmonary disease associated with functional limitation. Severe cardiac disease (e.g., New York Heart Association [NYHA] Functional Class III or IV, myocardial infarction within six months, ventricular tachyarrhythmias requiring ongoing treatment, unstable angina or other significant cardiovascular diseases)
17. History of a severe seizure disorder or current anticonvulsant use
18. Evidence of an active or suspected cancer or a history of malignancy where the risk of recurrence is more than or equal to 20% within two years. Patients with a lesion suspicious of hepatic malignancy on a screening imaging study will only be eligible if the likelihood of carcinoma is less than or equal to 10% following an appropriate evaluation
19. History of having received any systemic anti-neoplastic (including radiation) or immunomodulatory treatment (including systemic corticosteroids) more than or equal to six months prior to the first dose of study drug or the expectation that such treatment will be needed at any time during the study
20. Major organ transplantation
21. Thyroid disease with thyroid function poorly controlled on prescribed medications. Patients with elevated thyroid stimulating hormone or T4 concentrations, with elevation of antibodies to thyroid peroxidase and any clinical manifestations of thyroid disease are excluded
22. History or other evidence of severe retinopathy (e.g. CytoMegaloVirus [CMV] retinitis, macula degeneration) or clinically relevant ophthalmological disorder due to diabetes mellitus or hypertension
23. Inability or unwillingness to provide informed consent or abide by the requirements of the study
24. History or other evidence of severe illness or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study
25. Patients with a value of alfa-fetoprotein more than 100 ng/mL are excluded, unless stability (less than 10% increase) has been documented over at least the previous three months
26. Evidence of current hard drug(s) and/or alcohol abuse (20 g/day for women and 30 g/day for men)
27. Patients included in another trial or having been given investigational drugs within 12 weeks prior to screening

Recruitment start date


Recruitment end date



Countries of recruitment


Trial participating centre

Academic Medical Center (AMC)
1100 DD

Sponsor information


Academic Medical Center (AMC) (The Netherlands)

Sponsor details

Department of Hepato- and Gastroenterology
PO Box 22660
1100 DD

Sponsor type

Hospital/treatment centre



Funder type


Funder name

UCB (International)

Alternative name(s)

Funding Body Type

Funding Body Subtype


Funder name

Roche Nederland BV (The Netherlands)

Alternative name(s)

Funding Body Type

Funding Body Subtype


Funder name

Giliad Sciences (International)

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Basic results (scientific)

Publication list

2011 results in:
2017 results in:

Publication citations

  1. Results

    Takkenberg B, Terpstra V, Zaaijer H, Weegink C, Dijkgraaf M, Jansen P, Beld M, Reesink H, Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir., J. Gastroenterol. Hepatol., 2011, 26, 10, 1527-1535, doi: 10.1111/j.1440-1746.2011.06766.x.

Additional files

Editorial Notes

10/07/2018: Publication reference added.